Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A11206 | Pages: NA | Charts: NA | Tables: NA |
Viral clearance is an essential process in development of monoclonal antibodies, recombinant proteins and glycoproteins, tissue and blood-derived products, and medical devices. This is attributed to the fact that these products are at risk of contamination by bacteria and fungi, chemical impurities, and viruses. This influences the market for viral safety practices as well as incorporation into development chain of virus clearance processes. Biological products are vulnerable to bacteria, fungi, and viruses. Raw products and improper treatment of culture cause pollution. During downstream purification of therapeutic biologics, blood, and tissue-derived materials, viral clearance is an essential process. They are either removed or inactivated by viruses for manufacturing microbiologically stable goods. The viral clearance market is divided on the basis of viral clearance process, application, and end user. Moreover, viral clearance technique is divided into viral elimination and viral inactivation. On the basis of virus removal technologies, the viral removal section is sub-segmented into chromatography, precipitation, and nano filtration.
COVID-19 scenario analysis:
The COVID-19 pandemic has influenced demand for viral clearance greatly. The sector faces problems in production and supply chain, such as timely distribution of goods to end customers and inconsistent demand for products and services in the industry. Pharmaceutical and biotech firms across the globe are working together to combat the COVID-19 epidemic, from funding production of vaccinations to preparing supply chain issues for drugs. In this pandemic, there is an increase in demand of drugs and vaccination for treatment as around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the viral clearance industry is expected to witness a significant growth.
Growth in demand in pharmaceutical and biotechnological industries is the main driver of the global viral clearance industry. Moreover, the market development is also propelled by increase in number of new drug releases in different segments and related drug approval procedures.
Furthermore, the number of new drugs is growing and government policies are increasing. However, growth of the global virus clearance industry is greatly enhanced by quality assurance and quality management departments. However, high degree of consolidation act is going to restrain growth of the viral clearance service market.
Increase in number of mergers and acquisitions is anticipated to help the industry boost in the coming years. For instance, on 27 September 2019, Merck KGaA joined with Pfizer Inc. and launched new drug BAVENCIO for removal of virus.
On 1 March 2019, Clean Cells has joined with NAOBiOS for development of viral vaccines used for treatment of many diseases.
Key benefit of the report:
Questions answered in the viral clearance service market research report:
Key Market Segments
Key Market Players
Other Players